Therapy-related acute myelogenous leukemia and myelodysplastic syndrome

Current Oncology Reports

Volumn 9, Issue 5, 2007, Pages 373-377

  Borthakur, Gautam ^a   Estey, Elihu E ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; B RAF KINASE; BLEOMYCIN; CHLORAMBUCIL; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; MELPHALAN; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; NITROSOUREA DERIVATIVE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53; RAS PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETIC RISK; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; INCIDENCE; LEUKEMOGENESIS; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PREVALENCE; PROGNOSIS; REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS;

EID: 34548504331     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0050-z     Document Type: Review

References (46)

1. Mauritzson N, Albin M, Rylander L, et al.: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002, 16:2366-2378.
2. Pedersen-Bjergaard J, Specht L, Larsen SO, et al.: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987, ii:83-88.
3. Pui CH, Behm FG, Raimondi SC, et al.: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989, 321:136-142.
4. Pedersen-Bjergaard J, Larsen SO: Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982, 307:965-971.
5. Hake CR, Graubert TA, Fenske TS: Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007, 39:59-70.
6. Oosterveld M, Muus P, Suciu S, et al.: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia, two parallel studies adjusted for various prognostic factors. Leukemia 2002, 16:1615-1621.
7. Pedersen-Bjergaard J, Andersen MK, Christiansen DH: Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000, 95:3273-3279.
8. Berk PD, Goldberg JD, Silverstein MN, et al.: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981, 304:441-447.
9. Boice JD Jr, Greene MH, Killen JY Jr, et al.: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983, 309:1079-1084.
10. Kyle RA, Pierre RV, Bayrd ED: Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970, 283:1121-1125.
11. Reimer RR, Hoover R, Fraumeni JF Jr, Young RC: Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 1977, 297:177-181.
12. Cremin P, Flattery M, McCann SR, Daly PA: Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996, 7:745-746.
13. Pedersen-Bjergaard J, Daugaard G, et al.: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991, 338:359-363.
14. Ratain MJ, Kaminer LS, Bitran JD, et al.: Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987, 70:1412-1417.
15. Felix CA, Lange BJ, Hosler MR, et al.: Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res 1995, 55:4287-4292.
16. Stanulla M, Wang J, Chervinsky DS, et al.: DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Cell Biol 1997, 17:4070-4079.
17. Stanulla M, Chhalliyil P, Wang J, et al.: Mechanisms of MLL gene rearrangement: site-specific DNA cleavage within the breakpoint cluster region is independent of chromosomal context. Hum Mol Genet 2001, 10:2481-2491.
18. Mistry AR, Felix CA, Whitmarsh RJ, et al.: DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005, 352:1529-1538.
19. Zhang Y, Strissel P, Strick R, et al.: Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8,21) leukemia. Proc Natl Acad Sci U S A 2002, 99:3070-3075.
20. Frohling S, Scholl C, Gilliland DG, Levine RL: Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005, 23:6285-6295.
21. Gilliland DG, Jordan CT, Felix CA: The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004, 80-97.
22. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F: Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002, 16:2177-2184.
23. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK: Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006, 20:1943-1949.
24. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J: Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005, 19:2232-2240.
25. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17:1813-1819.
26. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J: Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001, 31:33-41.
27. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001, 19:1405-1413.
28. Roddam PL, Rollinson S, Kane E, et al.: Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 2000, 10:605-615.
29. Bolufer P, Collado M, Barragan E, et al.: Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007, 136:590-596.
30. Fern L, Pallis M, Ian CG, Seedhouse C, et al.: Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway, possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004, 126:63-71.
31. Jawad M, Seedhouse CH, Russell N, Plumb M: Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 2006, 108:3916-3918.
32. Seedhouse C, Faulkner R, Ashraf N, et al.: Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004, 10:2675-2680.
33. Gardin C, Chaibi P, de Revel T, et al.: Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Reflexion en Hematologie. Leukemia 1997, 11:16-21.
34. Oosterveld M, Suciu S, Verhoef G, et al.: The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 2003, 17:859-868.
35. Pagano L, Pulsoni A, Vignetti M, et al.: Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol 2005, 16:228-233.
36. Damiani D, Michieli M, Ermacora A, et al.: P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 1998, 83:290-297.
37. Rund D, Krichevsky S, Bar-Cohen S, et al.: Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005, 19:1919-1928.
38. Andersen MK, Larson RA, Mauritzson N, et al.: Balanced chromosome abnormalities inv(16) and t(15,17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002, 33:395-400.
39. Schnittger S, Bacher U, Haferlach C, et al.: Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16,16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia 2007, 21:725-731.
40. Pedersen-Bjergaard J, Philip P, Larsen SO, et al.: Therapy-related myelodysplasia and acute myeloid leukemia: cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993, 7:1975-1986.
41. Amann JM, Nip J, Strom DK, et al.: ETO, a target of t(8,21) in acute leukemia, makes distinct contacts with multiple historic deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 2001, 21:6470-6483.
42. Moe-Behrens GH, Pandolfi PP: Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol 2003, 7:139-159.
43. Wang J, Hoshino T, Redner RL, et al.: ETO, fusion partner in t(8,21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998, 95:10860-10865.
44. Lenz G, Dreyling M, Schiegnitz E, et al.: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004, 22:4926-4933.
45. Milligan DW, Kochethu G, Dearden C, et al.: High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006, 133:173-175.
46. Linassier C, Barin C, Calais G, et al.: Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 2000, 11:1289-1294.